Beijing Strong BiotechnologiesInc Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Beijing Strong BiotechnologiesInc ha un patrimonio netto totale di CN¥4.0B e un debito totale di CN¥1.2B, che porta il suo rapporto debito/patrimonio netto a 29.4%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥5.5B e CN¥1.5B. L'EBIT di Beijing Strong BiotechnologiesInc è CN¥639.4M rendendo il suo rapporto di copertura degli interessi 28.3. Ha liquidità e investimenti a breve termine pari a CN¥994.6M.

Informazioni chiave

29.4%

Rapporto debito/patrimonio netto

CN¥1.17b

Debito

Indice di copertura degli interessi	28.3x
Contanti	CN¥994.56m
Patrimonio netto	CN¥3.96b
Totale passività	CN¥1.49b
Totale attività	CN¥5.46b

Aggiornamenti recenti sulla salute finanziaria

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥2.6B ) di 300406 superano le sue passività a breve termine ( CN¥287.6M ).

Passività a lungo termine: Le attività a breve termine di 300406 ( CN¥2.6B ) superano le sue passività a lungo termine ( CN¥1.2B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 4.3% ) di 300406 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300406 è aumentato da 0% a 29.4% negli ultimi 5 anni.

Copertura del debito: Il debito di 300406 è ben coperto dal flusso di cassa operativo ( 53.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 300406 sono ben coperti dall'EBIT ( 28.3 x copertura).

Beijing Strong BiotechnologiesInc Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

New 90-day high - CN¥24.20

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane